DNA methylation-based non-invasive prenatal testing (NIPT) — the analysis of placental cfDNA methylation patterns enabling fetal aneuploidy, subchromosomal, and single-gene disorder detection from maternal blood, representing 25% of clinical methylation sequencing volume — creates the most commercially dynamic market segment, with the DNA Methylation Sequencing Market reflecting...